These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Group says FDA, advisory panels show bias toward drug approvals. Vedantam S Washington Post; 2006 Aug; ():A13. PubMed ID: 16941783 [No Abstract] [Full Text] [Related]
4. Food and Drug Administration proposed testing guidelines for reproduction studies. Revision Committee. FDA Guidelines for Developmental Toxicity and Reproduction, Food and Drug Administration. Collins TF; Sprando RL; Shackelford ME; Hansen DK; Welsh JJ Regul Toxicol Pharmacol; 1999 Aug; 30(1):29-38. PubMed ID: 10464044 [TBL] [Abstract][Full Text] [Related]
5. Advising under the influence?: conflicts of interest among FDA advisory committee members. Glode ER Food Drug Law J; 2002; 57(2):293-322. PubMed ID: 12437003 [No Abstract] [Full Text] [Related]
6. Olestra and the FDA. Blackburn H N Engl J Med; 1996 Apr; 334(15):984-6. PubMed ID: 8596603 [No Abstract] [Full Text] [Related]
7. Advisory committees at FDA: the Hinchey Amendment and "conflict of interest" waivers. Lietzan E J Health Law; 2006; 39(4):415-49. PubMed ID: 17402656 [TBL] [Abstract][Full Text] [Related]
8. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings. Lurie P MedGenMed; 2006 Oct; 8(4):22. PubMed ID: 17415305 [No Abstract] [Full Text] [Related]
9. Group makes recommendations to speed FDA device approvals. Scott L Mod Healthc; 1993 May; 23(19):23. PubMed ID: 10125877 [No Abstract] [Full Text] [Related]
10. The logistical requirements of current FDA review: format of documentation requested. Hattan D Regul Toxicol Pharmacol; 1996 Dec; 24(3):232-5. PubMed ID: 8975750 [No Abstract] [Full Text] [Related]
11. Communicating with the FDA: the "third rail" of a new model for drug development. Stanski DR; Orloff JJ J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890 [No Abstract] [Full Text] [Related]
12. Cancer chief embraces top drugs job. Wadman M Nature; 2005 Sep; 437(7059):606. PubMed ID: 16193009 [No Abstract] [Full Text] [Related]
13. The Portman Group and the AERC: a view from the United States of America. Mosher JF Addiction; 2005 Jan; 100(1):129-30. PubMed ID: 15598203 [No Abstract] [Full Text] [Related]
14. Interaction between optometrists and industry representatives. Optometry; 2009 Mar; 80(3):149-53. PubMed ID: 19271358 [No Abstract] [Full Text] [Related]
15. Science and regulation. Uncapping conflict of interest? Wood SF; Mador JK Science; 2013 Jun; 340(6137):1172-3. PubMed ID: 23744930 [No Abstract] [Full Text] [Related]
16. FDA changes afoot? Schultz's departure, conflict investigation might signify revamp under Hamburg. Rhea S Mod Healthc; 2009 Aug; 39(33):10. PubMed ID: 19714851 [No Abstract] [Full Text] [Related]
17. FDA announces reforms of drug review process. Anderson C Nature; 1991 Nov; 354(6350):173. PubMed ID: 1961242 [No Abstract] [Full Text] [Related]
18. FDA advisory committees: their purpose, how they work, and how you can become a member. Brady C Am J Gastroenterol; 2006 Apr; 101(4):689-91. PubMed ID: 16635215 [No Abstract] [Full Text] [Related]
19. FDA. Proposed guidelines for emergency research aim to quell confusion. Couzin J Science; 2006 Sep; 313(5792):1372-3. PubMed ID: 16959979 [No Abstract] [Full Text] [Related]
20. Vote of confidence for FDA advisory committees, but conflict of interest questions remain. Marwick C JAMA; 1992 Dec 23-30; 268(24):3417. PubMed ID: 1334160 [No Abstract] [Full Text] [Related] [Next] [New Search]